menu
    • menu

    Company profile for Zenara Pharma

    Biophore Mix GIF-PSE
    News
    Zenara`s Generics Nitazoxanide Receives Approval in US

    03 Feb 2025

    // FDA

    Zenara Pharma`s Generics Tafamidis Receives Tentative Approval in US

    21 Aug 2024

    // FDA

    Zenara's Generics Valsartan Receives Approval in US

    05 Aug 2024

    // FDA

    DATA COMPILATION
    #PharmaFlow

    Biophore

    Contact Supplier

    Website

    Simposio AFI

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Our state-of-the-art manufacturing facility at Cherlapally, Hyderabad is designed, equipped and maintained as per latest cGMP norms. The company’s manufacturing facility is fully equipped to manufacture both Solid Orals (Tablets, Capsules) and Oral liquids in various therapeutic categories. Zenara has in-house capability to ensure regulatory compliance in all the markets we operate in. We are constantly strengthening our global supply chain with customers in key markets including United States of America, Europe, Australia, New Zealand, Canada, Far East Asia, GCC (Gulf Cooperation Council), Brazil among others.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Zenara Pharmaindia-flag Flag
    Country
    Country
    India
    Address
    Address
    Plot No.83/B, 84 & 87 to 96, Phase - III, IDA Cherlapally, Hyderabad - 500 051
    Telephone
    Telephone
    +91 4027260848
    Client Email
    Email
    info@biophore.com
    Client Website
    Website
    https://www.zenarapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/zenara-pharma-pvt-ltd/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/home
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI China

    Not Confirmed

    envelop Contact Supplier

    CPhI China

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Zenara`s Generics Nitazoxanide Receives Approval in US
    Zenara`s Generics Nitazoxanide Receives Approval in US

    03 Feb 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214844

    FDA
    03 Feb 2025
    Share Share
    Zenara Pharma`s Generics Tafamidis Receives Tentative Approval in US
    Zenara Pharma`s Generics Tafamidis Receives Tentative Approval in US

    21 Aug 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218205

    FDA
    21 Aug 2024
    Share Share
    Zenara's Generics Valsartan Receives Approval in US
    Zenara's Generics Valsartan Receives Approval in US

    05 Aug 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218169

    FDA
    05 Aug 2024
    Share Share
    Biophore, its subsidiary Zenara, receive first approval for Cannabidiol in India
    Biophore, its subsidiary Zenara, receive first approval for Cannabidiol in India

    15 May 2023

    // HEALTH ET

    https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/biophore-its-subsidiary-zenara-pharma-receive-first-approval-for-cannabidiol-in-india/100251790

    HEALTH ET
    15 May 2023
    Share Share
    Zenara Pharma Generic Eliglustat Tartrate Receives Approval in the U.S
    Zenara Pharma Generic Eliglustat Tartrate Receives Approval in the U.S

    02 May 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212420

    FDA
    02 May 2023
    Share Share
    Zenara's Generic Ertugliflozin Receives Approval in the U.S.
    Zenara's Generic Ertugliflozin Receives Approval in the U.S.

    04 Apr 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216842

    FDA
    04 Apr 2023
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Biophore, Its Subsidiary Zenara Pharma, Receive First Approval for Cannabidiol in India

    Details:

    Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.


    Lead Product(s): Cannabidiol

    Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

    Study Phase: Approved FDFProduct Type: Controlled Substance

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 15, 2023

    Biophore CB

    01

    Zenara Pharma

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cannabidiol

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Biophore, Its Subsidiary Zenara Pharma, Receive First Approval for Cannabidiol in India

    Details : Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Inapplicable

    May 15, 2023

    Biophore CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zenara Pharma to Launch Generic Paxlovid Soon

    Details:

    Zenara said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment of mild-to-moderate Covid-19 in adults.


    Lead Product(s): Nirmatrelvir,Ritonavir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Paxzen

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Pfizer Inc

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 28, 2022

    Biophore CB

    02

    Zenara Pharma

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nirmatrelvir,Ritonavir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Pfizer Inc

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Zenara Pharma to Launch Generic Paxlovid Soon

    Details : Zenara said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment of mild-to-moderate Covid-19 in adults.

    Product Name : Paxzen

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 28, 2022

    Biophore CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zenara Pharma, a Biophore Subsidiary, Gets DCGI Nod for Favipiravir Tablets

    Details:

    Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.


    Lead Product(s): Favipiravir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Favizen

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 08, 2020

    Biophore CB

    03

    Zenara Pharma

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Favipiravir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Zenara Pharma, a Biophore Subsidiary, Gets DCGI Nod for Favipiravir Tablets

    Details : Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.

    Product Name : Favizen

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 08, 2020

    Biophore CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zenara Pharma Receives DCGI Approval to Manufacture, Sell Favipiravir Tablets

    Details:

    Zenara Pharma has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19.


    Lead Product(s): Favipiravir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Favizen

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 08, 2020

    Biophore CB

    04

    Zenara Pharma

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Favipiravir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Zenara Pharma Receives DCGI Approval to Manufacture, Sell Favipiravir Tablets

    Details : Zenara Pharma has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19.

    Product Name : Favizen

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 08, 2020

    Biophore CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : BREXPIPRAZOLE

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : USA

    BREXPIPRAZOLE

    Zenara Pharma

    Dosage Form : TABLET;ORAL

    Brand Name : BREXPIPRAZOLE

    Dosage Strength : 1MG

    Packaging :

    Approval Date :

    Application Number : 213477

    Regulatory Info :

    Registration Country : USA

    Biophore CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : BREXPIPRAZOLE

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : USA

    BREXPIPRAZOLE

    Zenara Pharma

    Dosage Form : TABLET;ORAL

    Brand Name : BREXPIPRAZOLE

    Dosage Strength : 3MG

    Packaging :

    Approval Date :

    Application Number : 213477

    Regulatory Info :

    Registration Country : USA

    Biophore CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : BREXPIPRAZOLE

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : USA

    BREXPIPRAZOLE

    Zenara Pharma

    Dosage Form : TABLET;ORAL

    Brand Name : BREXPIPRAZOLE

    Dosage Strength : 0.5MG

    Packaging :

    Approval Date :

    Application Number : 213477

    Regulatory Info :

    Registration Country : USA

    Biophore CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : BREXPIPRAZOLE

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : USA

    BREXPIPRAZOLE

    Zenara Pharma

    Dosage Form : TABLET;ORAL

    Brand Name : BREXPIPRAZOLE

    Dosage Strength : 2MG

    Packaging :

    Approval Date :

    Application Number : 213477

    Regulatory Info :

    Registration Country : USA

    Biophore CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : BREXPIPRAZOLE

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : USA

    BREXPIPRAZOLE

    Zenara Pharma

    Dosage Form : TABLET;ORAL

    Brand Name : BREXPIPRAZOLE

    Dosage Strength : 4MG

    Packaging :

    Approval Date :

    Application Number : 213477

    Regulatory Info :

    Registration Country : USA

    Biophore CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : BREXPIPRAZOLE

    India
    arrow
    FCE Pharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : USA

    BREXPIPRAZOLE

    Zenara Pharma

    Dosage Form : TABLET;ORAL

    Brand Name : BREXPIPRAZOLE

    Dosage Strength : 0.25MG

    Packaging :

    Approval Date :

    Application Number : 213477

    Regulatory Info :

    Registration Country : USA

    Biophore CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search